Please login to the form below
Country Reports
Is obesity really a problem in Brazil?
Obesity is on the rise in low- and middle-income countries, particularly in urban settings
Turkey: A growing pharma market with huge potential
The Turkish biopharma market offers many opportunities - if it can overcome its sustainability challenge
Creating a 21st century life sciences ecosystem
The UK’s life sciences minister on how government and pharma can encourage NHS uptake and innovation
The pharma business environment in the US
Tighter regulations, more pricing controls and increased international competition will drive market improvements
Turkey's pharma market is ripe for profitability
But will the highly efficient market be hindered by the government price referencing system?
Easier access to medicines in the UK?
Cutting through the NICE value-based assessment consultation to find out what’s at stake
The Chinese diabetes challenge
Marketing, communications and commercial relationships in China are full of pitfalls for the unwary, but not without great potential
Healthcare marketing compliance in the UK - prevention beats cure
UK's MHRA gives its views on rep training, pharma advertising and social media
Compulsory evaluation in France
French authorities will expect robust health economic cases to be made for some drugs
The oncology market in Canada
Ten per cent is not enough - simple estimates of the Canadian oncology market overlook a complex picture
ASEAN: Domestic vaccines manufacturers
Selling vaccines in the region places commercial considerations alongside humanitarian obligations
Putin - pharma’s friend or foe in Russia?
Assessing the opportunities and challenges for pharmaceutical companies entering the Russian market
Rise of generic medicines in Portugal
From a nation in love with branded medicines to one reliant on generics
How Russian lifestyles are affecting the nation's healthcare
Russian lifestyles present a significant challenge to the country’s health services
Unravelling China’s healthcare sector
How will health reforms, the tightening of regulations and the emergence of a domestic drug industry impact global pharmaceutical companies?
The MISTs of time - new emerging markets
As the BRIC foundations become firmly established, where next – and how soon – for those pharma companies seeking to exploit the developing markets?
Pharma investment in Indonesia
Healthcare reforms open up huge potential in the market to companies with a carefully tailored expansion strategy
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
